



**EAST LANCASHIRE HEALTH ECONOMY  
MEDICINES MANAGEMENT BOARD**

**MINUTES OF THE TEAMS MEETING 19<sup>th</sup> October 2022**

**PRESENT:**

Dr S Ramtoola (SR)	Consultant Physician, ELHT (Chairperson)
Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL ICB
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mr J Vaughan (JV)	Senior Medicines Commissioning Pharmacist NHS EL/BwD ICB
Ms Ana Batista (AB)	Medicines Information Pharmacist ELHT
Mr U Akram (UA)	Deputy Lead Pharmacist, LS CFT
Ms L Prince (LP)	Medicines Management Technician, EL ICB
Dr S Jackson (SJ)	GP Clinical Lead for Quality for Lancashire and South Cumbria ICS
Mr Neil Fletcher (NF)	Director of Pharmacy ELHT
Mr C Woods (CW)	Head of Contracting and Costing, Finance
Mrs H Robinson	Divisional Lead Pharmacist – MEC
Mr Abdullah Mistry	Cardiology Lead Pharmacist
Mr Dominic Sebastian	Consultant Intensivist and Deputy DMD for SAS
Dr Jasim Shihab	Neonatal

**IN ATTENDANCE:**

Dr Martin Hogg	Oncology Consultant, LTHTR
Dr Osama El Masri	Oncology Consultant, ELHT

**2022/152: APOLOGIES:**

Dr F Shah (FS)	GP/Consultant MFOP & Diabetes
Dr M Maher	Consultant Gynaecology & Sexual Health

**2022/153: DECLARATION OF INTEREST**

None declared - relevant to agenda items

**2022/154: MINUTES OF SEPTEMBER TEAMS MEETING:**

Accepted as accurate record.

**2022/155: MATTERS ARISING:**



**2021/101b:** ELMMB Membership – to remain on action matrix as a standing item for feedback. Currently awaiting appointment of new ICB Chief Pharmacist in November.

**2022/136g:** Biotin and Alpha tocopherol supplements: to be brought to November meeting and included prescribing data/numbers

**2022/145:** NICE Guidance July/August 2022 – for information, 2021 guidance was included in last months minutes. 2022 updated guidance included on this agenda.

### **2022/156 Formulary Updates**

- a. **Gepan Instill** (Chondroitin sulphate 0.2%): Currently RED traffic light on formulary for interstitial cystitis and other bladder conditions. Request for the traffic light to be AMBER for those patients that self-administer at home, with the GP continuing the prescribing on advice of the specialist. It was requested that a specific time period for follow up with secondary care be agreed before the change was accepted.  
**Action:** AB to contact Mr Hill to obtain more information before decision made.
- b. **Sucralfate enema** - Withdrawn from agenda
- c. **Tecovirimat** – for information that this drug has been made available via Blueteq as a treatment for patients hospitalised with Monkeypox viral infection. There are plans for use of the drug in sexual health clinics as part of a clinical trial pathway.  
**Traffic Light: RED**
- d. **Hypromellose 0.3% eye drops** – request to add cost-effective branded products to formulary. These will be AaproMel®, Dew Tear® and Lumecare®.  
**Traffic Light: GREEN**
- e. **Diltiazem MR 60mg tablets** - requested as an extra dose option to support titration of doses in coronary care patients.  
**Traffic Light: GREEN**
- f. **Valaciclovir 500mg tablets** - As a second line option, on advice of microbiology, in the treatment of herpes zoster and herpes simplex when acyclovir is not tolerated or ineffective.  
**Traffic Light: GREEN**
- g. **Azithromycin capsules** - capsules have been discontinued, remove from formulary. (Tablets will remain on formulary.)  
**Traffic Light: N/A**
- h. **Aectura® Breezhaler** (indacaterol/mometasone) – for use in the treatment of asthma.  
**Traffic Light: GREEN**
- i. **Enerzair® Breezhaler** (glycopyrronium/mometasone/indacaterol) – for maintenance treatment of asthma in adults in primary care following recommendation by a specialist.  
**Traffic Light: GREEN restricted**
- j. **Novorapid® to Trurapi®** - currently use Novorapid® as 3<sup>rd</sup> line bolus insulin. Request to consider using the biosimilar product, Trurapi®, in stable type 2 diabetic patients as there are significant cost savings. The risk and possible safety issues with switching patients was raised and the possible problems that may arise in primary care with



patient acceptance of the product as well as pressure on diabetic nurse time. Secondary Care tend to use Fiasp® in the minority of Type 2 diabetic patients requiring a fasting acting insulin.

**Action:** Formulary to be updated accordingly.

#### **2022/157 LSCMMG Consultations – October 2022 [deadline 4/11/22]**

- a. Oral nutritional supplementation guideline - consultation (please note content is the same as that consulted on in July)
- b. Sodium zirconium cyclosilicate prescriber information sheet - consultation

**Resolved:** Comments to be sent to LSCMMG

#### **2022/158 LSCMMG Recommendations– September 2022**

- a. Asthma desktop guideline – **updated**
- b. High dose morphine prescribing for chronic non-cancer pain – added
- c. Hydroxychloroquine information sheet – **updated**
- d. Edoxaban - Choice of DOAC for Stroke Prevention in Non-Valvular AF – **retired**
- e. Testosterone (transdermal) shared care guideline (following July LSCMMG) - added

**For Action:** items acknowledged by ELMMB. Website will be updated accordingly.

#### **2022/159 Strategic Commissioning Committee (SCC) Decisions – September 2022**

None (Group no longer active, awaiting update from LSCMMG)

#### **2022/160 Other Items**

**Colecalciferol 3000units/mL liquid dosing** - the dose was agreed last month as 7ml. However, to avoid wastage it was agreed that a dose of 6.5ml three times a week over a 5-week period would be more appropriate.

**Resolved:** Agreed to use 6.5ml as the recommended dose. Paediatric vitamin D guideline to be discussed with JV and the paediatric pharmacist for ELHT.

#### **2022/161 Other Items**

**RMOC FOC Form Pembrolizumab 2022-09-27** - request from consultant oncologists Dr Hogg and Dr El-Masri to use Pembrolizumab FOC from MSD pending update to the licence for high risk, early-stage, triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. Patients may participate in the scheme for up to 17 cycles of pembrolizumab or until progression of disease.

Further discussion is required to discuss ELHT capacity and support required to manage the use of the drug.

**Action:** ELHT to take further discussion



#### **2022/162 Other Items**

Professional Prescribing Restrictions V3 – for use with ELHE to outline legal and regulatory framework for the prescribing of controlled drugs by Health Care Professionals. The document provides clarity on level of competencies and qualification requirements when prescribing controlled drugs.

**Resolved:** Acknowledged by ELMMB

#### **2022/163 Other Items**

**Vitamin D Guidelines** – updated final version

**Resolved:** Final version acknowledged by ELMMB

#### **2022/164 NICE Guidance – July, August and September 2022**

**NG244 Urinary tract infection in under 16s: diagnosis and management.**

Updated 27<sup>th</sup> July 2022

**NG17 Type 1 diabetes in adults: diagnosis and management.**

Updated 17<sup>th</sup> August 2022

#### **2022/165 NICE Recommendations –September 2022**

Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal) is not recommended as an option as per NICE TA822  
**Traffic Light: BLACK**

Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer as an option by NICE. Approved in line with NICE TA823  
**NHS England Cancer Drug Fund** **Traffic Light: RED**

Dexamethasone intravitreal implant for treating diabetic macular oedema as a n option by NICE. Approved in line with NICE TA824  
**ICS Commissioned [Blueteq required]** **Traffic Light: RED**

Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis as an option by NICE. Approved in line with NICE TA825  
**NHS England Commissioned** **Traffic Light: RED**

Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal) is not recommended as an option as per NICE TA826  
**Traffic Light: BLACK**

Upadacitinib for treating active ankylosing spondylitis as an option by NICE. Approved in line with NICE TA829  
**ICS Commissioned [Blueteq required]** **Traffic Light: RED**

**Resolved:** Items acknowledged by ELMMB



**2022/166 NICE Highly Specialised Technologies – July and August 2022**

None this month

**2022/167 EAMS (Early access to medicines scheme) –September 2022**

**Cipaglucosidase alfa with miglustat** in the treatment of late-onset Pompe disease  
(Published 8 June 2021, Last updated 21 September 2022)

**Resolved:** Item acknowledged by ELMMB

**Standing Items:**

**2022/168 For Action/Information:** Lancashire & South Cumbria Medicines  
Management Group (LSCMMG)

DRAFT LSCMMG minutes 8<sup>th</sup> September 2022

**Resolved:** Minutes acknowledged.

**2022/169 For Action/Information:** Lancashire & South Cumbria FT Drugs  
and Therapeutics Committee

- a. Minutes from the Drugs and Therapeutics Committee Meeting Minutes 22<sup>nd</sup> September 2022
- b. Drugs and Therapeutics Committee Meeting Action Tracker updated September 22
- c. Drugs and Therapeutics Committee Meetings dates for 2023 To March 2024

Next meeting: Thursday 24<sup>th</sup> November 2022

**Resolved:** Minutes acknowledged.

**2022/170 For Action/Information:** Antimicrobial Stewardship Committee (ASC)

- a. ASC - minutes 9<sup>th</sup> August 2022
- b. ASC – Annual Report 2021- 2022 22  
[No September meeting]

**Resolved:** acknowledged by ELMMB.

**DATE OF NEXT MEETING – Wednesday 16<sup>th</sup> November 2022 12.30pm via ‘Microsoft Teams’**



**ACTION SHEET FROM  
EAST LANCASHIRE HEALTH ECONOMY  
MEDICINES MANAGEMENT BOARD**

**WEDNESDAY 20<sup>th</sup> July 2022**

<b>MINUTE NUMBER</b>	<b>DESCRIPTION</b>	<b>ACTION</b>	<b>DATE</b>
<b>2021/101b</b>	<b>ELMMB Membership</b> A review will be required to decide how ELMMB links with the ICS and ICB in the future and the policy for introduction of new drugs will required review as a result of that. Await full ICB structure	LR/VG	Jan 23
<b>2022/136 g</b>	<b>Biotin and Alpha tocopherol supplements</b> LR to investigate the numbers of patient receiving biotin and alpha tocopherol supplements and bring back to re-discuss in November	LR	Nov 22
<b>2022/156 a</b>	<b>Formulary Updates: Gepan Instill</b> Requested that a specific time period for follow up with secondary care be agreed before the change was accepted. AB to contact Mr Hill to obtain more information before decision made	AB	Nov 22